Last reviewed · How we verify
A Phase III,Randomized,Open Label Study Comparing Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa up to 2-3 Years for ≤ 45 Year Old Pre-menopausal Hormone Receptor-positive Breast Cancer
The present study is a randomized open-label -phase III study that aims to compare the efficacy and safety of the adjuvant chemotherapy with simultaneous or sequential application of Zoladex up to 2-3 years for ≤ 45 year old premenopausal hormone receptor-positive breast cancer.
Details
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 3 |
| Status | COMPLETED |
| Enrolment | 216 |
| Start date | 2009-06 |
| Completion | 2017-08 |
Conditions
- Breast Cancer
Interventions
- Zoladex
Primary outcomes
- Resumption of menstruation — 1 year
the Resumption that patients recover the natural menstrual or serum E2, FSH, LH return to the premenopausal range within 1 year after stopping Zoladex
Countries
China